| __timestamp | Iovance Biotherapeutics, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 54170000 |
| Thursday, January 1, 2015 | 12390000 | 65378000 |
| Friday, January 1, 2016 | 25602000 | 52263000 |
| Sunday, January 1, 2017 | 21262000 | 35072000 |
| Monday, January 1, 2018 | 28430000 | 27415000 |
| Tuesday, January 1, 2019 | 40849000 | 36983000 |
| Wednesday, January 1, 2020 | 60210000 | 50918000 |
| Friday, January 1, 2021 | 83664000 | 63586000 |
| Saturday, January 1, 2022 | 104097000 | 57967000 |
| Sunday, January 1, 2023 | 106916000 | 53107000 |
| Monday, January 1, 2024 | 23626000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Mesoblast Limited and Iovance Biotherapeutics, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, Iovance's SG&A expenses surged by over 1,000%, peaking in 2023. In contrast, Mesoblast's expenses fluctuated, with a notable 64% decrease from 2015 to 2024.
Iovance's aggressive spending strategy reflects its growth ambitions, while Mesoblast's more conservative approach suggests a focus on cost efficiency. Despite Iovance's higher expenses, Mesoblast's consistent management might offer a more sustainable model. Missing data for 2024 in Iovance's records leaves room for speculation on future strategies. As these companies navigate the biotech landscape, their SG&A management will be pivotal in determining their competitive edge.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Mesoblast Limited
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited
Who Optimizes SG&A Costs Better? GSK plc or Mesoblast Limited
Cost Management Insights: SG&A Expenses for argenx SE and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Mesoblast Limited
Verona Pharma plc vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Rhythm Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends